Literature DB >> 17576808

Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes.

Alison E Aitken1, Edward T Morgan.   

Abstract

Cytochromes P450 (P450s) are down-regulated in hepatocytes in response to inflammation and infection. This effect has been extensively studied in animal models, but significantly less is known about responses in humans and even less about responses in the absence of inducing agents. This article focuses on the effects of bacterial lipopolysaccaride (LPS), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF), interferon gamma (IFN), transforming growth factor-beta (TGF) and interleukin-1 beta (IL-1) on expression of CYP2B6 and the CYP2C mRNAs in human hepatocytes. These effects were compared with responses of the better studied and more abundant CYP3A4. CYP3A4 and CYP2C8 were down-regulated by all cytokine treatments. CYP2C18, which is expressed at very low levels in liver, was unaffected by cytokine treatments. The other CYP2Cs and CYP2B6 showed cytokine-specific effects. CYP2C9 and CYP2C19 showed almost identical response patterns, being down-regulated by IL-6 and TGF but not significantly affected by LPS, TNF, IFN, or IL-1. CYP2B6 mRNA responded only to IL-6 and IFN. IL-6 down-regulated the mRNAs of all P450s studied. Western blot analysis of P450 protein expression supported the mRNA data to a large extent, although some inconsistencies were observed. Our results show that human CYP2C8, 2C9, 2C18, 2C19, 2B6, and 3A4 responses to inflammation are independently regulated and indicate that this fine control may have a critical effect on human drug responses in disease states.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17576808      PMCID: PMC2171046          DOI: 10.1124/dmd.107.015511

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  40 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Lessons from the CYP3A4 promoter.

Authors:  Erin G Schuetz
Journal:  Mol Pharmacol       Date:  2004-02       Impact factor: 4.436

3.  Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure.

Authors:  Reginald F Frye; Virginia M Schneider; Carole S Frye; Arthur M Feldman
Journal:  J Card Fail       Date:  2002-10       Impact factor: 5.712

4.  Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver.

Authors:  T Lang; K Klein; J Fischer; A K Nüssler; P Neuhaus; U Hofmann; M Eichelbaum; M Schwab; U M Zanger
Journal:  Pharmacogenetics       Date:  2001-07

5.  Differential expression and function of CYP2C isoforms in human intestine and liver.

Authors:  Florian Läpple; Oliver von Richter; Martin F Fromm; Tanja Richter; Klaus P Thon; Hermann Wisser; Ernst-Ulrich Griese; Michel Eichelbaum; Kari T Kivistö
Journal:  Pharmacogenetics       Date:  2003-09

6.  Rapid transcriptional suppression of rat cytochrome P450 genes by endotoxin treatment and its inhibition by curcumin.

Authors:  Po-Yung Cheng; Molin Wang; Edward T Morgan
Journal:  J Pharmacol Exp Ther       Date:  2003-10-13       Impact factor: 4.030

7.  Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure.

Authors:  Joseph A Carcillo; Lesley Doughty; Danny Kofos; Reginald F Frye; Sandra S Kaplan; Howell Sasser; Gilbert J Burckart
Journal:  Intensive Care Med       Date:  2003-04-16       Impact factor: 17.440

8.  Transcriptional regulation of human CYP3A4 basal expression by CCAAT enhancer-binding protein alpha and hepatocyte nuclear factor-3 gamma.

Authors:  C Rodríguez-Antona; R Bort; R Jover; N Tindberg; M Ingelman-Sundberg; M J Gómez-Lechón; J V Castell
Journal:  Mol Pharmacol       Date:  2003-05       Impact factor: 4.436

9.  Reduction in cytochrome P-450 enzyme expression is associated with repression of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase response.

Authors:  Anne P Beigneux; Arthur H Moser; Judy K Shigenaga; Carl Grunfeld; Kenneth R Feingold
Journal:  Biochem Biophys Res Commun       Date:  2002-04-26       Impact factor: 3.575

10.  Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response.

Authors:  L P Rivory; K A Slaviero; S J Clarke
Journal:  Br J Cancer       Date:  2002-07-29       Impact factor: 7.640

View more
  116 in total

1.  Pregnane X receptor is required for interleukin-6-mediated down-regulation of cytochrome P450 3A4 in human hepatocytes.

Authors:  Jian Yang; Chunshu Hao; Dongfang Yang; Deshi Shi; Xiulong Song; Xiaofei Luan; Gang Hu; Bingfang Yan
Journal:  Toxicol Lett       Date:  2010-06-09       Impact factor: 4.372

2.  Obesity and its impact on drug therapy: are we ready for this change?

Authors:  Michael Neely; Stan Louie
Journal:  Clin Pharmacokinet       Date:  2011-12-01       Impact factor: 6.447

3.  DEC1 binding to the proximal promoter of CYP3A4 ascribes to the downregulation of CYP3A4 expression by IL-6 in primary human hepatocytes.

Authors:  Mao Zhao; Luan Xiaofei; Cao Gang; Liu Wei; Xiong Jing; Hu Gang; Chen Ruini; Ning Rui; Shang Wei; Yang Jian; Yan Bingfang
Journal:  Biochem Pharmacol       Date:  2012-06-21       Impact factor: 5.858

4.  Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells.

Authors:  Leslie Tompkins; Caitlin Lynch; Sam Haidar; James Polli; Hongbing Wang
Journal:  Pharm Res       Date:  2010-05-26       Impact factor: 4.200

Review 5.  Vaccine-Drug Interactions: Cytokines, Cytochromes, and Molecular Mechanisms.

Authors:  Paolo Pellegrino; Cristiana Perrotta; Emilio Clementi; Sonia Radice
Journal:  Drug Saf       Date:  2015-09       Impact factor: 5.606

6.  Altered cytochrome 2E1 and 3A P450-dependent drug metabolism in advanced ovarian cancer correlates to tumour-associated inflammation.

Authors:  Sebastian Trousil; Patrizia Lee; Robert J Edwards; Lynn Maslen; Jingky P Lozan-Kuehne; Ramya Ramaswami; Eric O Aboagye; Stephen Clarke; Christopher Liddle; Rohini Sharma
Journal:  Br J Pharmacol       Date:  2019-08-05       Impact factor: 8.739

7.  Effect of Gevokizumab on Interleukin-1β-Mediated Cytochrome P450 3A4 and Drug Transporter Repression in Cultured Human Hepatocytes.

Authors:  Amélie Moreau; Marc Le Vée; Elodie Jouan; Claire Denizot; Yannick Parmentier; Olivier Fardel
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

8.  Dual mechanisms of CYP3A protein regulation by proinflammatory cytokine stimulation in primary hepatocyte cultures.

Authors:  Choon-Myung Lee; Jan Pohl; Edward T Morgan
Journal:  Drug Metab Dispos       Date:  2009-01-26       Impact factor: 3.922

9.  Association between interleukin-18 promoter variants and tacrolimus pharmacokinetics in Chinese renal transplant patients.

Authors:  Jiazhen Xing; Xiaoqing Zhang; Junwei Fan; Bin Shen; Tongyi Men; Jianning Wang
Journal:  Eur J Clin Pharmacol       Date:  2014-12-10       Impact factor: 2.953

10.  Relationships between oxycodone pharmacokinetics, central symptoms, and serum interleukin-6 in cachectic cancer patients.

Authors:  Hikaru Sato; Takafumi Naito; Takuya Ishida; Junichi Kawakami
Journal:  Eur J Clin Pharmacol       Date:  2016-08-26       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.